New Medicare cap on anemia drugs could hammer Amgen

In another body blow to Amgen, regulators at Medicare say they have proposed limiting the amount of anemia drugs that it will reimburse for. Amgen reports that sales have already been sliding for anemia drugs and the regulators say that federal reimbursements are likely to drop 10 percent on the new rules. Medicare spends more money on anemia drugs than for any other pharmaceutical. Aranesp and Epogen, marketed by Amgen and J&J, bring in more than $10 billion a year and account for about half of Amgen's sales. That money has built Amgen into the biggest biotech company in the world and funded many of its new development programs.

- here's the report on the new rules from the Los Angeles Times
and here's the report from The Wall Street Journal

Suggested Articles

Bristol Myers Squibb may have bounced Jounce from its roster of inherited partners, but it’s hanging onto Anokion, a Swiss autoimmune-focused biotech.

The priority review action date sets Bristol Myers up to win approval for the bluebird-partnered anti-BCMA CAR-T therapy in late March.

The unidentified biotechs are drawn from the portfolio of a €150 million life science-focused fund that Index Ventures set up.